Clinical Trial Update: Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating safety and efficacy of different doses of 90Y-hPAM4 with gemcitabine in pancreatic cancer has completed phases 1 and 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 90Y-hPAM4
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Gilead Sciences | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED